Listen time: 27m 23s

About

Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Visit our Heart Failure Management Hub to discover a range of educational content to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for HF.

Articles

A3 - Veno-arterial ECMO Versus Impella™ Bleeding Complications in Cardiogenic Shock Patients on Dual Antiplatelet Therapy

Published:

11 November 2019

Citation:

Interventional Cardiology Review 2019;14(3 Suppl 1):A3.

SGLT2 Inhibitors and HF Prevention

Published:

04 November 2019

Citation:

Cardiac Failure Review 2019;5(3):169–72.

The Limitations of Symptom-based Heart Failure Management

Published:

24 May 2019

Citation:

Cardiac Failure Review 2019;5(2):74–7.

Renin–Angiotensin–Aldosterone System Inhibitors in the Elderly

Published:

24 May 2019

Citation:

Cardiac Failure Review 2019;5(2):70–3.